Association of TNF-related apoptosis inducing ligand receptor (TRAIL-R) gene polymorphisms in Iranian Azeri patients with multiple sclerosis by Amir Taghavi, Bita et al.
 





Association of TNF-related apoptosis inducing ligand receptor (TRAIL-R) 








, Seyed Ali Rahmani*
,3 
 
1Department of Genetics, Islamic Azad University, Tehran Medical Sciences Branch, Tehran, Iran 
2Department of Biology, Faculty of Sciences, University of Guilan, Rasht, Iran 
3Department of Biology, Ahar Branch, Islamic Azad University, Ahar, Iran 
 
*




     Multiple sclerosis (MS) is a chronic inflammatory demyelinating disorder of the central nervous 
system with various degrees of axonal damage. The TNF-related apoptosis inducing ligand receptor 
(TRAIL-R) might be playing an important role in the pathogenesis of MS. The objective of our study was 
to evaluate the association of two common polymorphisms is located in the TRAIL-R1 and TRAIL-R2 
gene, in the pathogenesis of MS.DNA was extracted from whole blood using the salting-out procedure. 
We genotyped two single nucleotide polymorphisms in particular regions with single strand conformation 
polymorphism (SSCP) and Results obtained from the sequence of some samples, were analyzed using 
DNAMAN software. The distribution of genotype frequencies was analyzed using Pearson‟s x
2
 test. 
Statistical significance was defined as p < 0.05.No Significant differences in SNP rs4872077 were found 
between the PRMS and PPMS groups and No association was found between the genotype status of the 
rs1001793 and rs4872077 polymorphisms and the age at onset, disease duration, EDSS. 
Our study suggests no association between TRAILR polymorphisms and MS Disease. Nevertheless, this 
polymorphisms does not appear to be a severity marker of the disease, neither modifying the clinical 
progression of MS nor its therapeutic response. 
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INTRODUCTION 
     Multiple sclerosis (MS, OMIM 126200) is one 
of the most common causes of neurological 
disability in young adults which is caused by 
interaction between environmental and inherited 
factors, where the transmission of signals in the 
central nervous system (CNS) vary from each 
other by lesion size and number, pathology, and 
clinical outcome. The most frequent forms of MS 
are relapsing remitting MS (RRMS), in which 
acute attacks are followed by complete or partial 
recovery, and primary progressive MS (PPMS), 
characterized by disease progression from onset 
[1-4].To date, it is supposed that MS is a chronic 
inflammatory condition, probably of autoimmune 
nature in which myelin-specific T cells seem to 
be responsible for the orchestration and 
prolongation of the autoimmune reaction that 
leads to oligodendrocyte damage and 
demyelination, in addition to axonal and neuronal 
damage [1-4]. A remarkably low number of 
susceptibility genes for MS have been identified 
so far. The disease shows familial clustering, and 
twin studies have revealed that a large portion of 
this clustering can be attributed to shared genes. 
But none of the candidate genes suggested to date 
has been shown to be essential or sufficient for 
disease development; the most association has 
obviously been proven with alleles of the major 
histocompatibility complex (MHC) and in 
particular with the haplotypes HLA-DQB1*0602, 
-DQA*0102, -DRB1*1501, -DRB5*0101 
[3,4,11]. However, MS is a heterogeneous  
condition in which the involved genes may be  
 




different in different subsets of patients [3-6].Genome 
wide linkage studies have identified MS susceptibility 
genes on at least eight human chromosomes, including 
chromosome 6, which carries the genes for TNF. TNF-
related apoptosis inducing ligand (TRAIL) is a newly 
identified member of the TNF/nerve growth factor 
super family, mapped on chromosome 3q26 [7, 13, 15]. 
Both TRAIL and TRAIL receptor genes are potential 
candidates for involvement in the development of 
multiple sclerosis [13-15]. Carlos Lopez-Gomez et.al 
has previously reported the effects of SNPs in TRAIL 
and TRAIL Receptors genes on MS susceptibility [13]. 
Several studies have searched for allelic variants 
associated with the response to IFN beta treatment in 
MS genetic and alterations in TRAIL/TRAIL receptor 
system might compromise apoptotic cell signaling [13-
15]. TRAILR-1 and TRAILR-2 genes which are the 
two common polymorphisms rs4872077 (T>C) and 
rs1001793 (G>A) transition polymorphisms are 
potential candidates for involvement in the development 
of multiple sclerosis [13]. The objective of this study is 
to investigate the association between TRAILR-1 and 
TRAILR-2 gene polymorphisms (rs4872077 and 
rs1001793) and susceptibility to MS and clinical course 
of the disease. 
 
MATERIALS AND METHODS 
DNA Isolation  
     From October 2014 to June 2015, all participants 
involved in this comparative case (Group 1) and 
control (Group 2; Absence of Clinical symptoms 
and Family history) study were informed about the 
study and written informed consent was obtained 
before blood collection all individuals involved in this 
comparative case (Group 1) and control (Group 2; 
Absence of Clinical symptoms and Family history) 
study provided us with written informed consents for 
the genetic analysis according to Iran Medical 
Committee. The study population consisted of 80 
MS patients and 80 healthy individuals as 
controls, all being unrelated Iranian Azari from 
East Azerbaijan of Iran. We therefore studied age 
and sex-matched attendants and relatives of MS 
patients and healthy staff at the clinic. All patients 
had clinical or laboratory supported definite MS 
according to the Poser criteria [8] or fulfilled the 
criteria of McDonald for MS [19] and the patients 
were classified as relapsing–remitting or primary 
progressive according to the initial course of the 
disease. Blood samples were collected from 
volunteers and placed in tubes that contained an 
EDTA anticoagulant. Genomic DNA was 
extracted from the white blood cells using the 
method of Miller et al. [9]. DNA concentrations 
were determined by a UV spectrophotometer at 
260 nm. 
Genotyping  
     The Single-strand conformation 
polymorphism (SSCP) technique makes possible 
the detection of both known and unknown single 
point mutations and polymorphisms in products 
of the PCR. Optimization of SSCP analysis to 
detect the maximum number of mutations requires 
electrophoresis under carefully controlled conditions at 
different temperatures, using different gels. We have 
analyzed the specific region of TRAIL-R1 and TRAIL-
R2 gene. SSCP analysis identified aberrant bands. A 
100-bp DNA Ladder (Fermentas Vilnius, Lithuania) 
was used as a size standard for each gel lane. PCR was 
carried out at 95 °C denature for 5 min, followed by 35 
cycles of 95 °C denature for 20 sec, 58 °C annealing for 
20 sec and 72 °C extension 30 min. Sequences of 
Primers used in Polymerase Chain Reactions in „Table 
1‟. To validate the obtained results, samples of PCR 
products were sent to Bioneer Corporation (Daejeon, 
Republic of Korea) for sequencing. Direct sequence 
analysis of these aberrantly migrating bands led to the 
identification of TRAIL-R1 and TRAIL-R2 mutations. 
 
Table 1.Sequences of Primers Used in Polymerase Chain Reactions 
PCR Product 
(bp) 









rs1001793  TGCAGCTCTCACCTCTCAAACA  R 
1.F: Forward primer 
2.R: Reverse primer 
 
 





     The student t-test was used to test the 
difference between the groups with regards to 
mean age, and ᵡ
2 
statistics. The distribution of 
genotype frequencies was analyzed using 
Pearson‟s ᵡ
2
 test. P value less than 0.05 was 
considered statistically significant. In order to 
check if any individual SNP was associated with 
MS susceptibility, genotype frequencies were 
compared, using a likelihood ratio test. 
 
RESULTS 
     Our study was performed on a case and 
control design consisting of 160 people. The 
clinical data for the two examined groups are  
displayed in Table 2. The median age of onset of 
disease in PPMS group was 38.2±9.3 years and 
for PRMS group was 36.5±9.4. As the groups 
were age and sex matched, there were no 
differences by gender or mean age (p=0.898); 
the age at onset in the PPMS patients was higher 
and the disease duration was shorter than in the  
PRMS patients but not significantly so (p=0.510  
and p=0.345 respectively). No substantial 
differences in SNP rs4872077 were found 
between the PRMS and PPMS groups. 
(ᶍ
2
=3.040; df =1; p=0.082 and ᶍ
2
=0.720; df=1; 
p=0.142). According to our data, there was no 
significant difference between patients with MS 
and the healthy subjects. No association was 
found between the genotype status of the 
rs1001793 and rs4872077 polymorphisms and 
the age at onset, disease duration, and Expanded 
Disability Status Scale (EDSS). Analysis of 
genotype and allele frequencies of the 
rs1001793 polymorphism is shown in Tables 3, 
4 and rs4872077 polymorphism in Table 5, 6. 
The genotypes and allele frequencies were not 
different in patient and control groups (the 
frequencies of SNP rs4872077 (ᶍ
2
=0.42, 
P=0.514) and rs1001793 (ᶍ
2
=2.3, P=0.127)). Future 
studies are required to further examine the findings as 
these results do not support a role of TRAIL-R gene 
polymorphisms in susceptibility to MS. 
 





Male/Female Age (years) 






PPMS 42/38 49.3±10.2 38.2±9.3 10.9±9.1 5.8±1.8 
PRMS 42/38 49.4±9.6 36.5±9.4 12.8±7.9 2.9±1.8 
P - 0.898 0.510 0.345 <0.001 
 
 Table 3.Genotypic and Allele frequencies of the rs1001793 polymorphism 
group Genotype Frequency (%) PPMS (n=40) PRMS (n=40) 
1.00 
AA 3 (3.8) 1 2 
GA 13 (16.2) 6 7 
GG 64 (80.0) 33 31 
Total 80 (100) 40 40 
2.00 
AA 1 (1.2) - - 
GA 9 (11.1) - - 
GG 70 (87.7) - - 
Total 80 (100) - - 
 
 




 Table 4.The distribution of genotype frequency of the rs1001793 polymorphism 









1 0.127 - - 
Continuity Correctionb 1.707 1 0.191 - - 
Likelihood Ratio 2.350 1 0.125 - - 
Fisher's Exact Test - - - 0.191 0.095 
Linear-by-Linear 
Association 
2.308 1 0.129 - - 
N of Valid Cases 160 - - - - 
       a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 12.50. 
       b. Computed only for a 2x2 table 
 
 Table 5.The distribution of genotype frequency of the rs4872077 polymorphism 
group Genotype Frequency (%) PPMS (n=40) PRMS (n=40) 
1.00 
CC 3 (3.8) 1 2 
TC 11 (13.8) 3 8 
TT 66 (82.5) 36 30 
Total 80 (100.0) 40 40 
2.00 
CC 3 (3.7) - - 
TC 8 (10) - - 
TT 69 (86.3) - - 
Total 80 (100) - - 
 
 
       Table 6.The distribution of genotype frequency of the rs4872077 polymorphism 








a 1 0.514 - - 
Continuity Correctionb 0.190 1 0.663 - - 
Likelihood Ratio 0.428 1 0.513 - - 






N of Valid Cases 160 - - - - 
      a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 12.50. 
      b. Computed only for a 2x2 table 
 
DISCUSSION 
     MS is a common disease which is most likely 
caused by interaction between multiple common 
allelic variations of genes. The possible 
association between multiple sclerosis (MS) and  
 
TRAIL Receptor polymorphisms has already 
been analyzed in several studies, with 
conflicting results [3, 13]. 
In general, association studies are very powerful  
 




in dissecting the genetic contribution to complex 
diseases; however, there are many examples of 
association with a candidate gene followed by 
studies which could not confirm the earlier 
reports. It seems that other polymorphisms in 
different positions of TNF-α, other cytokines, 
and also their interaction should be taken into 
account in the study of MS susceptibility [4-6, 
20]. Recently, some genome-wide association 
studies (GWAS) have been performed through 
analyzing a large number of SNPs, 
simultaneously, based on chip technology. They 
demonstrated no significant relationship 
between TRAIL gene polymorphism and MS, 
which is consistent with our findings [1, 10, 12]. 
To date, 55% of the Iranian population belongs 
to the 15-30 years age group. MS typically 
occurs in young patients and the predominance 
of young population in Iran may justify the high 
prevalence of MS in this country [16-17]. This 
paper did not reveal significant differences 
between the polymorphisms and the Expanded 
Disability Status Scale (EDSS). We have not 
found any publication in which the relationship 
between genotypes and EDSS was examined. A 
study of TRAILR-1 and TRAILR-2 genotypes 
in Spanish patients has shown rs4872077, in 
TRAILR-1 gene, p = 0.005, OR = 1.72; and 
rs1001793 in TRAILR-2 gene, p = 0.012, OR = 
0.84. The combination of the alleles G/T/A in 
these SNPs appears to be associated with a 
reduced risk of developing MS (p = 2.12×10⁻5, 
OR = 0.59). The results obtained in previous 
studies suggest that genes of the TRAIL/TRAIL 
receptor system exert a genetic influence on MS 
[13]. It is notable that in our study, the SNP 
rs4872077 located in the TRAIL-R1 gene does 
not show any association with MS. The 
protective role of the A allele in rs1001793 
polymorphism does not show any association 
with MS in our study. The findings of the  
present study might suggest that the rs4872077 
T to C and rs1001793 G to A transition 
polymorphisms in the TRAILR-1 and TRAILR-
2 is less common in MS patients in the Iranian 
Azeri Turkish population. This is not in accord 
with the proposed role of TRAILR in the 
pathophysiology of clinical characteristics in 
MS. This genetic complexity may also be 
partially responsible for the disagreement among 
results reported by various studies. 
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